ANIX

Anixa BiosciencesF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

No material screener or newswire events are stored for this ticker yet.

Sentiment decomposition

30-day score

Company-55%

Macro-30%

Pulse-15%

The 30-day sentiment score is a decayed blend of Company, Macro, and Pulse components.

Recent headlines

Headline

Time

Relevance

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

2026-04-01

23%

External coverage

Anixa Biosciences CEO Calls 2026 Pivotal as Breast Cancer Vaccine, Ovarian CAR-T Advance

2026-02-10

23%

External coverage

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

2026-02-09

External coverage

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

2026-02-02

External coverage

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

2025-11-17

External coverage

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

2025-09-22

23%

External coverage

Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals

2025-09-16

63%

External coverage

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

2025-08-04

23%

External coverage

As of 2026-04-01 • Updated scheduledSource: News desk